1. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Issue 1 (December 2017) Authors: Bianchini, Giampaolo; Kiermaier, Astrid; Bianchi, Giulia; Im, Young-Hyuck; Pienkowski, Tadeusz; Liu, Mei-Ching; Tseng, Ling-Ming; Dowsett, Mitch; Zabaglo, Lila; Kirk, Sarah; Szado, Tania; Eng-Wong, Jennifer; Amler, Lukas; Valagussa, Pinuccia; Gianni, Luca Journal: Breast cancer research Issue: Volume 19:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. (January 2018) Authors: Schneeweiss, Andreas; Chia, Stephen; Hickish, Tamas; Harvey, Vernon; Eniu, Alexandru; Waldron-Lynch, Maeve; Eng-Wong, Jennifer; Kirk, Sarah; Cortés, Javier Journal: European journal of cancer Issue: Volume 89(2018) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Issue 10 (October 2018) Authors: Tabernero, Josep; Hoff, Paulo M; Shen, Lin; Ohtsu, Atsushi; Shah, Manish A; Cheng, Karen; Song, Chunyan; Wu, Haiyan; Eng-Wong, Jennifer; Kim, Katherine; Kang, Yoon-Koo Journal: Lancet oncology Issue: Volume 19:Issue 10(2018) Page Start: 1372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Issue 1 (January 2017) Authors: Luen, Stephen J; Salgado, Roberto; Fox, Stephen; Savas, Peter; Eng-Wong, Jennifer; Clark, Emma; Kiermaier, Astrid; Swain, Sandra M; Baselga, Jose; Michiels, Stefan; Loi, Sherene Journal: Lancet oncology Issue: Volume 18:Issue 1(2017:Jan.) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗